{"id":"W3214392141","doi":"10.1182/blood-2021-152984","title":"Magnetismm-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Carfilzomib; Multiple myeloma; Internal medicine; Refractory (planetary science); Bortezomib; Population; Clinical endpoint; Oncology; Proteasome inhibitor; Phases of clinical research; Lenalidomide; Clinical trial","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00351821,0.002021923,0.002222939,0.0005135662,0.0007286307,0.001296319,0.001247427,0.002151724,0.005205119],"category_scores_gemma":[0.001495717,0.0008569407,0.00218857,0.0004302803,0.00119052,0.001402897,0.0005344322,0.004318082,0.001190401],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001248724,"about_ca_system_score_gemma":0.002304929,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008201122,"about_ca_topic_score_gemma":0.002340224,"domain_scores_codex":[0.9991403,0.000452524,0.00004180886,0.0001426766,0.0000844961,0.0001382188],"domain_scores_gemma":[0.9989138,0.000172581,0.000254138,0.00008044098,0.00008736067,0.0004917462],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8853648,0.06181583,0.002884209,0.0007699494,0.001525901,0.0001395861,0.000182604,0.0007697061,0.01323581,0.0002313841,0.003039527,0.0300407],"study_design_scores_gemma":[0.828444,0.1649213,0.003554903,0.00002638332,0.0003205513,0.00009099891,0.0000295852,0.0005772526,0.0007141797,0.0001732573,0.001127277,0.00002022957],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9781668,0.003568608,0.0009582355,0.001441003,0.0003553515,0.01107214,0.002149385,0.0002157833,0.002072801],"genre_scores_gemma":[0.9718959,0.001982089,0.003649757,0.003108615,0.000523196,0.01243943,0.002705502,0.0000598384,0.003635823],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005205119,"threshold_uncertainty_score":0.01860631,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03114659338313195,"score_gpt":0.3333311392751745,"score_spread":0.3021845458920425,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}